HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Botaneco debuts Hydresia

This article was originally published in The Rose Sheet

Executive Summary

SemBioSys division unveils first branded line of oilbody-based ingredients Oct. 2 at the Society of Cosmetic Chemists trade show in Los Angeles, Calif. Hydresia - a base for moisturizers, body lotions, washes, fragrances and other personal-care items - offers skin barrier protection, anti-aging hydration and skin absorption properties to formulators looking for a "green" alternative to ingredients like petrolatum and mineral oil, company says. The firm is interested in working with marketing partners on a "co-branding" strategy to tout Hydresia's benefits in finished products (1"The Rose Sheet" Sept. 10, 2007, p. 6)...

You may also be interested in...

Biotech Firm SemBioSys Gets Serious About Personal Care With Botaneco Unit

Canadian biotech firm SemBioSys is putting greater focus on the personal-care ingredient supply side of its business with the launch of a new Botaneco unit devoted to the development of functional - and natural - oil systems

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts